CareDx (NASDAQ:CDNA) Issues Quarterly Earnings Results

CareDx (NASDAQ:CDNA) issued its earnings results on Thursday. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.25 by $0.45, FiscalAI reports. The firm had revenue of $139.36 million during the quarter, compared to the consensus estimate of $121.96 million. CareDx had a return on equity of 2.87% and a net margin of 24.23%. The business’s quarterly revenue was up 39.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.03 earnings per share.

Here are the key takeaways from CareDx’s conference call:

• Strong financial performance: Q3 revenue rose 39% year over year to $139 million, testing volume increased 51% to 75,900 tests, adjusted EBITDA doubled to $30 million, and the company ended the quarter with $250 million in cash and no debt. Management raised full-year 2026 revenue guidance to $520 million–$530 million and adjusted EBITDA guidance to $90 million–$100 million.
• The transplant franchise delivered 21% year-over-year volume growth, led by continued adoption in kidney and lung, while 21 centers are now live on Epic Aura. Management said it expects roughly half of transplant orders to flow through electronic medical-record integrations by year-end, supporting further workflow adoption.
• NavDx specialty oncology revenue grew 37% year over year on a comparable basis, and CareDx is expanding its commercial team, patient access services, electronic ordering, and billing infrastructure. Management believes NavDx revenue per test can increase from approximately $823 to $1,000 or more over time as evidence and adoption expand.
• CareDx remains on track to launch AlloHeme for AML and MDS recurrence monitoring in Q1 2027 and broaden HistoMap Kidney availability in 2027. However, management indicated that meaningful AlloHeme revenue is likely to emerge in 2029, with coverage potentially materializing in 2028, while NavDx radiation-de-escalation evidence remains based primarily on early phase II studies.

CareDx Price Performance

Shares of NASDAQ CDNA opened at $71.52 on Friday. The firm has a 50-day moving average of $59.12 and a 200 day moving average of $33.30. The stock has a market cap of $3.70 billion, a P/E ratio of 34.55 and a beta of 2.38. CareDx has a 1 year low of $14.23 and a 1 year high of $73.43.

Insiders Place Their Bets

In related news, Director George Bickerstaff, III sold 20,000 shares of CareDx stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $46.28, for a total value of $925,600.00. Following the completion of the sale, the director directly owned 134,061 shares in the company, valued at approximately $6,204,343.08. This trade represents a 12.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christine Cournoyer sold 16,000 shares of the firm’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $46.94, for a total value of $751,040.00. Following the completion of the transaction, the director owned 42,943 shares in the company, valued at approximately $2,015,744.42. This trade represents a 27.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on CDNA shares. Zacks Research downgraded shares of CareDx from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 2nd. Canaccord Genuity Group set a $99.00 price target on shares of CareDx in a research note on Friday. William Blair raised shares of CareDx to a “hold” rating in a research report on Thursday, July 16th. HC Wainwright restated a “neutral” rating and issued a $46.00 price objective on shares of CareDx in a research report on Friday, July 31st. Finally, Craig Hallum raised shares of CareDx from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a research note on Monday, August 3rd. Three investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $64.40.

CareDx Company Profile

CareDx, Inc is a healthcare diagnostics company focused on improving the care of organ-transplant patients. The company develops and commercializes noninvasive tests and digital tools intended to help physicians assess transplant-organ health, identify potential rejection, and support long-term patient management.

Its offerings include AlloSure donor-derived cell-free DNA tests for monitoring transplant recipients, AlloMap gene-expression testing for heart-transplant patients, and HeartCare, which combines AlloMap and AlloSure results.